GlassScriptPhysician profile
Jason M Citta
NPI 1538187893
$5,855.92
in general payments reported to CMS, 2019-2025
41 companies · $596 in 2025
The $596 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $597 · 2020: $688 · 2021: $1,015 · 2022: $1,098 · 2023: $1,016 · 2024: $846 · 2025: $596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,457.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $808.74 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $576.75 | 2019-2025 | Repatha, Otezla, Evenity |
| Janssen Pharmaceuticals, INC | $517.63 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $408.32 | 2020-2024 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $384.66 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $360.58 | 2019-2025 | |
| Daiichi Sankyo INC. | $248.75 | 2020-2024 | Injectafer |
| Exact Sciences Corporation | $240.20 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $219.25 | 2020-2025 | |
| Astellas Pharma US INC | $197.90 | 2019-2024 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $175.65 | 2020-2024 | Breztri |
| Sanofi-Aventis U.S. LLC | $174.57 | 2020-2023 | |
| Otsuka America Pharmaceutical, INC. | $165.56 | 2021-2025 | Rexulti |
| Eisai INC. | $140.21 | 2020-2024 | |
| Novartis Pharmaceuticals Corporation | $118.15 | 2020-2023 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $95.05 | 2020-2025 | Eliquis |
| Supernus Pharmaceuticals, INC. | $84.62 | 2020-2021 | |
| Ani Pharmaceuticals, INC. | $78.48 | 2025 | Purified Cortrophin Gel |
| Mylan Specialty L.P. | $77.35 | 2019-2024 | Yupelri |
| Merck Sharp & Dohme LLC | $75.21 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Xeris Pharmaceuticals, INC. | $72.83 | 2020-2025 | Gvoke Hypopen, Keveyis |
| Organon LLC | $70.90 | 2022-2023 | Nexplanon |
| Dexcom, INC. | $63.33 | 2024-2025 | Dexcom G6 Transmitter |
| Biowound Solutions, INC. | $45.64 | 2025 | Bio-Connekt |
| Glaxosmithkline, LLC. | $39.80 | 2020-2024 | Trelegy Ellipta |
| Allergan, INC. | $39.77 | 2019-2020 | |
| Genentech USA, INC. | $39.53 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $35.46 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $35.11 | 2023-2025 | Voquezna |
| Soleno Therapeutics, INC. | $34.33 | 2025 | Vykat Xr |
| Sanofi Pasteur INC. | $30.69 | 2021-2022 | |
| Philips North America LLC | $29.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.56 | 2022-2025 | |
| Abbott Laboratories | $24.39 | 2024 | Freestyle Libre 3 |
| Mirum Pharmaceuticals, INC. | $22.36 | 2025 | Cholbam |
| Amarin Pharma, INC. | $18.89 | 2019 | |
| Axsome Therapeutics, INC. | $17.92 | 2023 | Sunosi |
| Lexicon Pharmaceuticals, INC. | $17.12 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $16.99 | 2022 | |
| Gilead Sciences, INC. | $16.71 | 2019 | |
| Travere Therapeutics, INC. | $8.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Citta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.